Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD Expects Alaris Infusion Pump To Return To US Market Next Year

Executive Summary

The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.

You may also be interested in...



Slow Q1 For Baxter, But Board Remains Confident Of Turnaround

Baxter International recorded slight revenue increases during quarter one of 2021, with sales still impacted by COVID-19. Its board remains optimistic , pointing towards new product releases and “operational strength” as redeeming factors.

Class I Recall: More Alaris Infusion Pumps Yanked From Market

The US FDA has labeled the recall of nearly 2,500 Alaris Model 8100 infusion pumps as high-risk class I.

BD Names COO Thomas Polen As Next CEO; Vince Forlenza Will Retire In January

Polen led BD’s $24bn acquisition of Bard in 2017 and the $12bn acquisition of CareFusion in 2015. Forlenza has been with BD for almost 40 years, including eight as CEO.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel